ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1075

The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)

Philip J. Clements1, Donald Tashkin1, Michael Roth1, Dinesh Khanna2, Daniel E. Furst3, Chi-hong Tseng1, Elizabeth R. Volkmann1 and Robert Elashoff4, 1Medicine, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Medicine, University of Michigan, Ann Arbor, MI, 3Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 4Biomath, University of California Los Angeles, David Geffen School Of Medicine, Los Angeles, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: cyclophosphamide, interstitial lung disease, mycophenolate mofetil, randomized trials and systemic sclerosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 8, 2015

Session Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's - Clinical Aspects and Therapeutics I

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Demonstrate that the course of forced vital capacity (FVC)
over 2-years was better in SSc patients with symptomatic ILD treated with oral
MMF for two years than with oral CYC for one year followed by placebo during
the second year in a blinded randomized controlled trial.

Methods: Entry criteria: 1980 ACR criteria for SSc; disease duration of  =< 7
years from 1st non-Raynaud sign or symptom; moderate dyspnea (Level
2 of the Magnitude of Task scale of the Mahler Baseline Dyspnea Index [BDI];
%FVC between 45% and 80%; and any ground-glass opacification on chest
high-resolution computed tomography (HRCT).

            At
baseline and every 3 months during the 2-year trial, physical exams (including
modified Rodnan skin scoring or MRSS), lung function testing and patient-reported
outcomes were completed: Scleroderma Health Assessment Questionnaire (disability
index [HAQ-DI] and 5 100-mm visual analogue scales); SF-36, and transition
dyspnea index (TDI).

            Patients
were randomized to Arm A (oral CYC 2 mg/kg/day for one year followed by
matching placebo for the second year) or Arm B (matching MMF up to 1500 mg BID for
2 years).

            Results:
142 patients were randomized; 106 completed the 2-year evaluation. With the
exception of MRSS, which was higher in the MMF group (15.3 in MMF vs 14.1 in
CYC, p=xxx) the baseline characteristics were not different between treatment
groups.

            In
preliminary analyses,  the course of FVC showed comparable
improvement in both treatment groups at 24 months (see figure).  Improvements in
both treatment groups were noted in TDI (increase of 2.24 in CYC vs 1.86 in MMF,
) and in MRSS (decline of 6.1 units in CYC vs 2.9 units in MMF).

            More
patients in the CYC arm withdrew from study treatment prematurely (36 in CYC
and 20 in MMF) (p=0.019).Of all the subjects with end-point data 23% assigned
to CYC received alternative therapy after stopping study treatment (MMF in 8,
Rituximab in 1, tocilizimab in 1 and IV-CYC in 2) and 4% assigned to MMF
received alternative treatment (po CYC in 1 and IV-CYC in 1) after stopping
study treatment..

Weight loss
(NS) and leukopenia/thrombocytopenia (p<0.05) occurred more frequently in
the CYC arm

            Conclusion:
In this large, double blind, RTC, we found: 1) At 24 months the improvement in %FVC
was comparable in the two treatment groups. 2) The TDI and MRSS improved in
both treatment arms but there was a trend favoring improvements in the CYC
group. 3) Significantly fewer premature withdrawals were noted in the MMF arm.
4) Leukopenia/thrombocytopenia were noted significantly less frequently in the
MMF arm5) It is unclear how the use of alternative medications in SSc patients
who withdrew prematurely from study treatments, particularly in the CYC
patients, could have influenced the results.

In summary both CYC and MMF are efficacious for treatment of
SSc-ILD.

 


Disclosure: P. J. Clements, None; D. Tashkin, None; M. Roth, None; D. Khanna, Bristol-Myers Squibb, 2,EMD Serono, 2,Genentech and Biogen IDEC Inc., 2,Bayer, 5,Biogen Idec, 5,Cytori, 5,EMD Serono, 5,Forward, 5,Genentech and Biogen IDEC Inc., 5,Gilead, 5,Lycera, 5,Seattle Genetics, 5; D. E. Furst, Gilead, 2,GlaxoSmithKline, 2,NIH, 2,Novartis Pharmaceutical Corporation, 2,Pfizer Inc, 2,Roche Pharmaceuticals, 2,Genentech and Biogen IDEC Inc., 2,UCB, 2,Abbvie, 5,Actelion Pharmaceuticals US, 5,Amgen, 5,Bristol-Myers Squibb, 5,Cytori, 5,Janssen Pharmaceutica Product, L.P., 5,Gilead, 5,GlaxoSmithKline, 5,NIH, 5,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 5,Roche Pharmaceuticals, 5,Genentech and Biogen IDEC Inc., 5,UCB, 5,Abbvie, 8,Actelion Pharmaceuticals US, 8,Bristol-Myers Squibb, 2,Amgen, 2,Actelion Pharmaceuticals US, 2,Abbvie, 2,UCB, 8; C. H. Tseng, None; E. R. Volkmann, None; R. Elashoff, None.

To cite this abstract in AMA style:

Clements PJ, Tashkin D, Roth M, Khanna D, Furst DE, Tseng CH, Volkmann ER, Elashoff R. The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc) [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-scleroderma-lung-study-ii-sls-ii-shows-that-both-oral-cyclophosphamide-cyc-and-mycophenolate-mofitil-mmf-are-efficacious-in-treating-progressive-interstitial-lung-disease-ild-in-patients-w/. Accessed January 21, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-scleroderma-lung-study-ii-sls-ii-shows-that-both-oral-cyclophosphamide-cyc-and-mycophenolate-mofitil-mmf-are-efficacious-in-treating-progressive-interstitial-lung-disease-ild-in-patients-w/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.